Study Investigating a PEGylated Recombinant Factor VIII (BAX 855) for Hemophilia A (PROLONG-ATE Study)
type: MedicalStudy
description: A Phase 2/3, Multi-Center, Open Label Study of Efficacy, Safety, and Pharmacokinetics of PEGylated Recombinant Factor VIII (BAX 855) Administered for Prophylaxis and Treatment of Bleeding in Previously Treated Patients With Severe Hemophilia A
status: COMPLETED
study design: INTERVENTIONAL
phase: PHASE2,PHASE3
start date: 2013-01-31
end date: 2014-07-17
license: https://creativecommons.org/publicdomain/zero/1.0/
source: https://clinicaltrials.gov/study/NCT01736475
source organization: US National Library of Medicine
publisher: AI Analytics
sponsor: Baxalta now part of Shire
study subject: Hemophilia A
keywords: PHASE2,PHASE3
keywords: INTERVENTIONAL
keywords: COMPLETED
keywords: Hemophilia A

AI Analytics
type: Organization